Vaccines-2013 - OMICS Group

Recommendations

Info

The companyGenPhar, Inc. (GenPhar or Company) is aleading development-stage company in theburgeoning field of biodefense. GenPhar’sscientists have developed a novel andproprietary vaccine platform technology thatcan support the development of multivalentvaccines against many infectious diseases.GenPhar is currently working undercontracts with the United States ArmyMedical Research Institute for InfectiousDisease (USAMRIID) to develop a bivalent(protects against two different strains) Ebolavaccine, a trivalent (against three strains)Marburg vaccine, and a panfilo-vaccine thatprotects people against infection by fivestrains of the hemorrhagic fever viruses. Thehemorrhagic fever viruses are “the mostlethal viruses known to mankind” andcauses death in over 95% of those infected; therefore, these viruses can be usedas extremely lethal biological weapons that threaten the national security of theUnited States. Under a separate contract, GenPhar is working with the US Navy todevelop a tetravalent (against four strains) dengue vaccine. In addition to the greatneed of dengue vaccines by the US military, the worldwide market for denguevaccine is huge. Two thirds of the world’s population (2.5 billion), live in dengueinfested areas, with millions of new cases annually.GenPhar’s business model is todevelop and produce the neededbiodefense vaccines for the Government,while sustaining continuous financialgrowth for the company by manufacturingthe vaccines for the Government vaccinestockpile, and for the continuousreplacement of the vaccines due to expire.In addition, GenPhar will utilize its vaccineplatform to develop vaccines with higheconomical and social impacts, such asAIDS and hepatitis C vaccines, for the civilian markets.Page 24
Because of heightened awareness of the country’s vulnerability to biologicalattacks and the increased threats of new or rare lethal diseases (such as outbreaksof West Nile virus in the US, Ebola in Africa and SARS in Southeast Asia andChina), GenPhar’s business strategy has become uniquely attractive for adevelopment stage company.GenPhar’s Platform Technology: GenPhar’s patented technology platform isextremely adaptive and can support vaccine development for infectious diseaseswith high social and economical impacts, such as AIDS, hepatitis C and atherapeutic hepatitis B vaccine. These vaccines have shown unprecedentedabilities to induce powerful humoral and cellular immune responses in small animaland non-human primate tests. Because of the enormous demands of thebiodefense vaccines and the shortened pathway to market in the United States,GenPhar has elected to concentrate on its biodefense vaccines and has enteredinto a joint venture with a Chinese biotechnology company. GenPhar licensed itsvaccines for AIDS and hepatitis B to the JV. In exchange, the JV will manufacture,test, achieve approval for and commercialize the vaccines for sale in the GreaterChina market. GenPhar owns a minority interest in the JV. More importantly,GenPhar retains the rights to these vaccines elsewhere in the world.GenPhar’s first phase of commercialization is to provide licensed rights ofbiodefense vaccines that include the Ebola, Marburg, and dengue vaccines to thegovernment. The second phase will be to manufacture the vaccines for theDepartment of Defense (including its allies) and the Department of HomelandSecurity to stockpile and replace any expired vaccines in the following years. Thethird phase will be to commercialize the dengue, AIDS, and hepatic C vaccines forcivilian markets. The company will strive to provide financial returns to its investorswith profits of the licensing and sale of the biodefense vaccines and provide itsinvestors with an exit strategy by entering the public stock market at an appropriatetime.Contract Information:John Dong, M.D., Ph.D.CEOGenPhar, Inc.dongj@genphar.comGenPhar Research and Production FacilityPage 25
Page 1 and 2: 111 th OMICS Group ConferenceJuly 2
Page 3 and 4: Medical SciencesISSNAddiction Resea
Page 5 and 6: Impact Factors (IF) and Index Coper
Page 7 and 8: 111 th OMICS Group Conference3 rd I
Page 9 and 10: Journal of Clinical & Cellular Immu
Page 15 and 16: Clinical Microbiology-2013OMICS Gro
Page 17 and 18: Immunology Summit-2013OMICS Group i
Page 19 and 20: Probiotics-2013OMICS Group is organ
Page 21 and 22: Virology-2013OMICS Group is organiz
Page 23: 111 th OMICS Group Conference3 rd I
Page 33 and 34: Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36: Nikolai Petrovsky, J Vaccines Vacci
Page 39 and 40: Robert E. Sievers et al., J Vaccine
Page 41 and 42: Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44: Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46: Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48: Diane Longo et al., J Vaccines Vacc
Page 49 and 50: Track 33: Novel Approaches in Desig
Page 51 and 52: Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54: Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56: A. Bennett Jenson et al., J Vaccine
Page 57 and 58: Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76:
Humberto Hernandez et al., J Vaccin
Page 77 and 78:
Nisha Nair et al., J Vaccines Vacci
Page 79 and 80:
Leow Yee et al., J Vaccines Vaccin
Page 81 and 82:
Kaissar Tabynov et al., J Vaccines
Page 83 and 84:
Teena Mohan et al., J Vaccines Vacc
Page 85 and 86:
Track 5 & 95: Manufacturing, Produc
Page 87 and 88:
Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90:
Obradovic Zarema et al., J Vaccines
Page 91 and 92:
Abdur Razzaque Sarker et al., J Vac
Page 93 and 94:
Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96:
111 th OMICS Group Conference3 rd I
Page 97 and 98:
Regina Heidenreich et al., J Vaccin
Page 99 and 100:
Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102:
Zafer Kurugol et al., J Vaccines Va
Page 103 and 104:
Ates Kara et al., J Vaccines Vaccin
Page 105 and 106:
Yurong Tan et al., J Vaccines Vacci
Page 107 and 108:
Deryabin P.N. et al., J Vaccines Va
Page 109 and 110:
Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112:
Byung Chul Kim et al., J Vaccines V
Page 113 and 114:
STS. Chitradevi et al., J Vaccines
Page 115 and 116:
Yan Liang et al., J Vaccines Vaccin
Page 117 and 118:
Page 119 and 120:
Afshineh Latifynia et al., J Vaccin
Page 121 and 122:
Hemanta Koley et al., J Vaccines Va
Page 123 and 124:
Aleksandar Masic et al., J Vaccines
Page 125 and 126:
Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128:
Oladipo Aina et al., J Vaccines Vac
Page 129 and 130:
Aiswariya Chidambaram, J Vaccines V
Page 131 and 132:
Birhanu Hurisa et al., J Vaccines V
Page 133 and 134:
Ghaffarifar F et al., J Vaccines Va
Page 135 and 136:
Mathan Periasamy et al., J Vaccines
Page 137 and 138:
Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140:
Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142:
Page 143 and 144:
Birhanu Hurisa et al., J Vaccines V
Page 145 and 146:
Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148:
Belachew Etana et al., J Vaccines V
Page 149 and 150:
Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152:
Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154:
Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156:
Sandeepkumar R. Chauhan et al., J V
Page 157 and 158:
Veronica Rainone et al., J Vaccines
Page 159 and 160:
Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?